Bluejay Diagnostics Inc Cash Flow Conversion Efficiency
Bluejay Diagnostics Inc cash flow conversion efficiency. Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has a cash flow conversion efficiency ratio of -0.380x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bluejay Diagnostics Inc (2019–2025)
Cash flow conversion efficiency of Bluejay Diagnostics Inc from 2019 to 2025. This chart illustrates how Bluejay Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Bluejay Diagnostics Inc for real-time trading data and today's change.
Bluejay Diagnostics Inc Cash Flow Conversion Ratio Explained
Bluejay Diagnostics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bluejay Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluejay Diagnostics Inc ranked by their cash flow conversion efficiency. Also see market cap of Bluejay Diagnostics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QUHUO LTD SP.ADR/10 CL.A
F:9J40
|
N/A |
|
Redcentric
LSE:RCN
|
0.133x |
|
Hadasit Bio
TA:HDST
|
-0.033x |
|
France Tourisme Immobilier SA
PA:MLFTI
|
N/A |
|
Northern Venture Trust
LSE:NVT
|
-0.025x |
|
Propell Holdings Ltd
AU:PHL
|
-0.056x |
|
Tullow Oil PLC
LSE:TLW
|
-0.557x |
|
ZAZZ Energy of Sweden AB
ST:ZAZZ-B
|
-0.063x |
Annual Cash Flow Conversion Efficiency for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bluejay Diagnostics Inc from 2019 to 2025. Review Bluejay Diagnostics Inc (BJDX) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.98 Million | $-6.05 Million | -1.013x | +25.77% |
| 2024-12-31 | $5.73 Million | $-7.82 Million | -1.365x | +52.48% |
| 2023-12-31 | $2.89 Million | $-8.31 Million | -2.872x | -328.15% |
| 2022-12-31 | $11.54 Million | $-7.74 Million | -0.671x | -213.08% |
| 2021-12-31 | $20.38 Million | $-4.37 Million | -0.214x | -277.15% |
| 2020-12-31 | $-4.21 Million | $-508.71K | 0.121x | -79.02% |
| 2019-12-31 | $-2.93 Million | $-1.69 Million | 0.576x | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more